RNA aptamers and their therapeutic and diagnostic applications

International Journal of Biochemistry and Molecular Biology

Volumn 4, Issue 1, 2013, Pages 27-40

  Germer, Katherine ^a   Leonard, Marissa ^a   Zhang, Xiaoting ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Drug delivery; RNA aptamer; RNA nanotechnology; RNA therapy; SELEX

Indexed keywords

APTAMER; CD4 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOPROTEIN GP 120; PEGAPTANIB; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RNA APTAMER; TECHNETIUM 99M; UNCLASSIFIED DRUG; VASCULOTROPIN;

BREAST CANCER; CELL SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT; COLORECTAL CANCER; COMBINATORIAL CHEMISTRY; CROSS OVER SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT; DIABETIC MACULAR EDEMA; DIAGNOSTIC TEST; GLIOBLASTOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMAGING; LUNG CANCER; PROSTATE CANCER; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RNA INTERFERENCE; SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT; TISSUE SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT;

EID: 84876025119     PISSN: None     EISSN: 21524114     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Ellington AD and Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990; 346: 818-822.
2. Tuerk C and Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990; 249: 505-510.
3. Gold L, Janjic N, Jarvis T, Schneider D, Walker JJ, Wilcox SK and Zichi D. Aptamers and the RNA World, Past and Present. Cold Spring Harb Perspect Biol 2012; 4.
4. Que-Gewirth NS and Sullenger BA. Gene therapy progress and prospects: RNA aptamers. Gene Ther 2007; 14: 283-291.
5. Dua P, Kim S and Lee DK. Nucleic acid aptamers targeting cell-surface proteins. Methods 2011; 54: 215-225.
6. Keefe AD, Pai S and Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov 2010; 9: 537-550.
7. Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, Langer R and Farokhzad OC. Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol 2008; 26: 442-449.
8. Soontornworajit B and Wang Y. Nucleic acid aptamers for clinical diagnosis: cell detection and molecular imaging. Anal Bioanal Chem 2011; 399: 1591-1599.
9. Thiel KW and Giangrande PH. Intracellular delivery of RNA-based therapeutics using aptamers. Ther Deliv 2010; 1: 849-861.
10. Yan AC and Levy M. Aptamers and aptamer targeted delivery. RNA Biol 2009; 6: 316-320.
11. Jayasena SD. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem 1999; 45: 1628-1650.
12. Guo P. The emerging field of RNA nanotechnology. Nat Nanotechnol 2010; 5: 833-842.
13. Cox JC, Rudolph P and Ellington AD. Automated RNA selection. Biotechnol Prog 1998; 14: 845-850.
14. Mi J, Liu Y, Rabbani ZN, Yang Z, Urban JH, Sullenger BA and Clary BM. In vivo selection of tumor-targeting RNA motifs. Nat Chem Biol 2010; 6: 22-24.
15. Ng EW and Adamis AP. Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. Ann N Y Acad Sci 2006; 1082: 151-171.
16. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS and Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-985.
17. Leung DW, Cachianes G, Kuang WJ, Goeddel DV and Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-1309.
18. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611.
19. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J and Connolly DT. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246: 1309-1312.
20. Ruckman J, Green LS, Beeson J, Waugh S, Gillette WL, Henninger DD, Claesson-Welsh L and Janjic N. 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 1998; 273: 20556-20567.
21. Jellinek D, Green LS, Bell C and Janjic N. Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor. Biochemistry 1994; 33: 10450-10456.
22. Green LS, Jellinek D, Bell C, Beebe LA, Feistner BD, Gill SC, Jucker FM and Janjic N. Nucleaseresistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. Chem Biol 1995; 2: 683-695.
23. Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR and Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006; 5: 123-132.
24. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R and Greene MI. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 2007; 117: 2051-2058.
25. Yarden Y and Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137.
26. O'Rourke DM, Kao GD, Singh N, Park BW, Muschel RJ, Wu CJ and Greene MI. Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells. Proc Natl Acad Sci U S A 1998; 95: 10842-10847.
27. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
28. Chen CH, Chernis GA, Hoang VQ and Landgraf R. Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. Proc Natl Acad Sci U S A 2003; 100: 9226-9231.
29. Li N, Larson T, Nguyen HH, Sokolov KV and Ellington AD. Directed evolution of gold nanoparticle delivery to cells. Chem Commun (Camb) 2010; 46: 392-394.
30. Li N, Nguyen HH, Byrom M and Ellington AD. Inhibition of cell proliferation by an anti-EGFR aptamer. PLoS One 2011; 6: e20299.
31. Kang S. Isolation of RNA Aptamers Targeting HER-2-overexpressing Breast Cancer Cells Using Cell-SELEX. Bulletin of the Korean Chemical Society 2009; 30: 1827-1831.
32. Castanotto D and Rossi JJ. The promises and pitfalls of RNA-interference-based therapeutics. Nature 2009; 457: 426-433.
33. Zamore PD, Tuschl T, Sharp PA and Bartel DP. RNAi: double-stranded RNA directs the ATPdependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000; 101: 25-33.
34. Matzke MA and Birchler JA. RNAi-mediated pathways in the nucleus. Nat Rev Genet 2005; 6: 24-35.
35. Tolia NH and Joshua-Tor L. Slicer and the argonautes. Nat Chem Biol 2007; 3: 36-43.
36. McNamara JO 2nd, Andrechek ER, Wang Y, Viles KD, Rempel RE, Gilboa E, Sullenger BA I and Giangrande PH. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006; 24: 1005-1015.
37. Lupold SE, Hicke BJ, Lin Y and Coffey DS. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res 2002; 62: 4029-4033.
38. Chu TC, Twu KY, Ellington AD and Levy M. Aptamer mediated siRNA delivery. Nucleic Acids Res 2006; 34: e73.
39. Dassie JP, Liu XY, Thomas GS, Whitaker RM, Thiel KW, Stockdale KR, Meyerholz DK, McCaffrey AP, McNamara JO 2nd and Giangrande PH. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 2009; 27: 839-849.
40. Pastor F, Kolonias D, Giangrande PH and Gilboa E. Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature 2010; 465: 227-230.
41. Ni X, Zhang Y, Ribas J, Chowdhury WH, Castanares M, Zhang Z, Laiho M, DeWeese TL and Lupold SE. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J Clin Invest 2011; 121: 2383-2390.
42. Guo S, Tschammer N, Mohammed S and Guo P. Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA. Hum Gene Ther 2005; 16: 1097-1109.
43. Liu J, Guo S, Cinier M, Shlyakhtenko LS, Shu Y, Chen C, Shen G and Guo P. Fabrication of stable and RNase-resistant RNA nanoparticles active in gearing the nanomotors for viral DNA packaging. ACS Nano 2011; 5: 237-246.
44. Abdelmawla S, Guo S, Zhang L, Pulukuri SM, Patankar P, Conley P, Trebley J, Guo P and Li QX. Pharmacological characterization of chemically synthesized monomeric phi29 pRNA nanoparticles for systemic delivery. Mol Ther 2011; 19: 1312-1322.
45. Shu D, Shu Y, Haque F, Abdelmawla S and Guo P. Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics. Nat Nanotechnol 2011; 6: 658-667.
46. Zhou J, Li H, Li S, Zaia J and Rossi JJ. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther 2008; 16: 1481-1489.
47. Zhou J and Rossi JJ. Current progress in the development of RNAi-based therapeutics for HIV-1. Gene Ther 2011; 18: 1134-1138.
48. Zhou J, Swiderski P, Li H, Zhang J, Neff CP, Akkina R and Rossi JJ. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res 2009; 37: 3094-3109.
49. Zhou J, Shu Y, Guo P, Smith DD and Rossi JJ. Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition. Methods 2011; 54: 284-294.
50. Tombelli S, Minunni M and Mascini M. Aptamers-based assays for diagnostics, environmental and food analysis. Biomol Eng 2007; 24: 191-200.
51. Pieve CD, Perkins AC and Missailidis S. Anti-MUC1 aptamers: radiolabelling with (99m)Tc and biodistribution in MCF-7 tumour-bearing mice. Nucl Med Biol 2009; 36: 703-710.
52. Wan Y, Kim YT, Li N, Cho SK, Bachoo R, Ellington AD and Iqbal SM. Surface-immobilized aptamers for cancer cell isolation and microscopic cytology. Cancer Res 2010; 70: 9371-9380.
53. Barfod A, Persson T and Lindh J. In vitro selection of RNA aptamers against a conserved region of the Plasmodium falciparum erythrocyte membrane protein 1. Parasitol Res 2009; 105: 1557-1566.
54. Ringquist S and Parma D. Anti-L-selectin oligonucleotide ligands recognize CD62L-positive leukocytes: binding affinity and specificity of univalent and bivalent ligands. Cytometry 1998; 33: 394-405.
55. Brown M and Wittwer C. Flow cytometry: principles and clinical applications in hematology. Clin Chem 2000; 46: 1221-1229.
56. Drolet DW, Moon-McDermott L and Romig TS. An enzyme-linked oligonucleotide assay. Nat Biotechnol 1996; 14: 1021-1025.
57. Li Y, Lee HJ and Corn RM. Detection of protein biomarkers using RNA aptamer microarrays and enzymatically amplified surface plasmon resonance imaging. Anal Chem 2007; 79: 1082-1088.
58. Zhang Y, Chen Y, Han D, Ocsoy I and Tan W. Aptamers selected by cell-SELEX for application in cancer studies. Bioanalysis 2010; 2: 907-918.
59. Windbichler N and Schroeder R. Isolation of specific RNA-binding proteins using the streptomycin-binding RNA aptamer. Nature Protocols 2006; 1: 638-U634.
60. Bagalkot V, Farokhzad OC, Langer R and Jon S. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed Engl 2006; 45: 8149-8152.
61. Brockstedt U, Uzarowska A, Montpetit A, Pfau W and Labuda D. In vitro evolution of RNA aptamers recognizing carcinogenic aromatic amines. Biochem Biophys Res Commun 2004; 313: 1004-1008.
62. Ulrich H, Ippolito JE, Pagan OR, Eterovic VA, Hann RM, Shi H, Lis JT, Eldefrawi ME and Hess GP. In vitro selection of RNA molecules that displace cocaine from the membrane-bound nicotinic acetylcholine receptor. Proc Natl Acad Sci U S A 1998; 95: 14051-14056.
63. Ulrich H, Magdesian MH, Alves MJ and Colli W. In vitro selection of RNA aptamers that bind to cell adhesion receptors of Trypanosoma cruzi and inhibit cell invasion. J Biol Chem 2002; 277: 20756-20762.
64. Huang Z, Pei W, Jayaseelan S, Shi H and Niu L. RNA aptamers selected against the GluR2 glutamate receptor channel. Biochemistry 2007; 46: 12648-12655.
65. Rentmeister A, Bill A, Wahle T, Walter J and Famulok M. RNA aptamers selectively modulate protein recruitment to the cytoplasmic domain of beta-secretase BACE1 in vitro. RNA 2006; 12: 1650-1660.
66. Santulli-Marotto S, Nair SK, Rusconi C, Sullenger B and Gilboa E. Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer Res 2003; 63: 7483-7489.
67. Li N, Ebright JN, Stovall GM, Chen X, Nguyen HH, Singh A, Syrett A and Ellington AD. Technical and biological issues relevant to cell typing with aptamers. J Proteome Res 2009; 8: 2438-2448.
68. Liu Y, Kuan CT, Mi J, Zhang X, Clary BM, Bigner DD and Sullenger BA. Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis. Biol Chem 2009; 390: 137-144.
69. Khaled A, Guo S, Li F and Guo P. Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology. Nano Lett 2005; 5: 1797-1808.
70. Pagratis NC, Bell C, Chang YF, Jennings S, Fitzwater T, Jellinek D and Dang C. Potent 2'-amino-, and 2'-fluoro-2'-deoxyribonucleotide RNA inhibitors of keratinocyte growth factor. Nat Biotechnol 1997; 15: 68-73.
71. O'Connell D, Koenig A, Jennings S, Hicke B, Han HL, Fitzwater T, Chang YF, Varki N, Parma D and Varki A. Calcium-dependent oligonucleotide antagonists specific for L-selectin. Proc Natl Acad Sci U S A 1996; 93: 5883-5887.
72. Daniels DA, Sohal AK, Rees S and Grisshammer R. Generation of RNA aptamers to the Gprotein-coupled receptor for neurotensin, NTS1. Anal Biochem 2002; 305: 214-226.
73. Huang DB, Vu D, Cassiday LA, Zimmerman JM, Maher LJ 3rd and Ghosh G. Crystal structure of NF-kappaB (p50)2 complexed to a high-affinity RNA aptamer. Proc Natl Acad Sci U S A 2003; 100: 9268-9273.
74. Khvorova A, Kwak YG, Tamkun M, Majerfeld I and Yarus M. RNAs that bind and change the permeability of phospholipid membranes. Proc Natl Acad Sci U S A 1999; 96: 10649-10654.
75. Kimoto M, Sakamoto K, Shirouzu M, Hirao I and Yokoyama S. RNA aptamers that specifically bind to the Ras-binding domain of Raf-1. FEBS Lett 1998; 441: 322-326.
76. Cerchia L, Duconge F, Pestourie C, Boulay J, Aissouni Y, Gombert K, Tavitian B, de Franciscis V and Libri D. Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol 2005; 3: e123.
77. Choi KH, Park MW, Lee SY, Jeon MY, Kim MY, Lee HK, Yu J, Kim HJ, Han K, Lee H, Park K, Park WJ and Jeong S. Intracellular expression of the T-cell factor-1 RNA aptamer as an intramer. Mol Cancer Ther 2006; 5: 2428-2434.
78. Hicke BJ, Stephens AW, Gould T, Chang YF, Lynott CK, Heil J, Borkowski S, Hilger CS, Cook G, Warren S and Schmidt PG. Tumor targeting by an aptamer. J Nucl Med 2006; 47: 668-678.
79. Ohuchi SP, Ohtsu T and Nakamura Y. Selection of RNA aptamers against recombinant transforming growth factor-beta type III receptor displayed on cell surface. Biochimie 2006; 88: 897-904.
80. McNamara JO, Kolonias D, Pastor F, Mittler RS, Chen L, Giangrande PH, Sullenger B and Gilboa E. Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J Clin Invest 2008; 118: 376-386.
81. Dollins CM, Nair S, Boczkowski D, Lee J, Layzer JM, Gilboa E and Sullenger BA. Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. Chem Biol 2008; 15: 675-682.
82. Lee JH, Canny MD, De Erkenez A, Krilleke D, Ng YS, Shima DT, Pardi A and Jucker F. A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc Natl Acad Sci U S A 2005; 102: 18902-18907.
83. Bardeesy N and Pelletier J. Overlapping RNA and DNA binding domains of the wt1 tumor suppressor gene product. Nucleic Acids Res 1998; 26: 1784-1792.
84. Mi J, Zhang X, Giangrande PH, McNamara JO 2nd, Nimjee SM, Sarraf-Yazdi S, Sullenger BA and Clary BM. Targeted inhibition of alphavbeta3 integrin with an RNA aptamer impairs endothelial cell growth and survival. Biochem Biophys Res Commun 2005; 338: 956-963.
85. Lee HK, Choi YS, Park YA and Jeong S. Modulation of oncogenic transcription and alternative splicing by beta-catenin and an RNA aptamer in colon cancer cells. Cancer Res 2006; 66: 10560-10566.